(Q43239379)

17 November 2017

title

Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer (English)

1 reference

17 November 2017

1 reference

1 reference

2

1 reference

17 November 2017

Heidi J Gray

1

1 reference

17 November 2017

Ron E Swensen

series ordinal

3

1 reference

17 November 2017

Hisham K Tamimi

series ordinal

4

1 reference

17 November 2017

Barbara A Goff

series ordinal

5

1 reference

17 November 2017

language of work or name

English

0 references

publication date

17 November 2009

1 reference

17 November 2017

1 reference

17 November 2017

volume

116

1 reference

17 November 2017

issue

3

1 reference

17 November 2017

page(s)

340-344

1 reference

17 November 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Principles and practice of intraperitoneal chemotherapy for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.054

10.1016/J.YGYNO.2009.10.054

7 January 2021

Identifiers

DOI

1 reference

17 November 2017

1 reference